Dolutegravir (DTG) is a highly efficacious and well tolerated antiretroviral (ART) for the treatment of HIV infection. Although on the preferred treatment list for people living with HIV, it is not a treatment option for pregnant women because data on efficacy, tolerability during pregnancy, and teratogenicity are limited.
We performed a descriptive cohort analysis of pregnant women from the Drexel Womens Care Center (WCC) receiving DTG for HIV treatment during pregnancy. The Drexel WCC reports maternal and fetal outcomes to the Antiretroviral Pregnancy Registry, a national de-identified database of pregnant women with HIV on ART. Here, we evaluate maternal and fetal outcomes of mother-infant pairs with DTG use during pregnancy between 2015 and 2017.
During the study period, nineteen pregnant women used DTG for HIV treatment; 14 had live deliveries and 5 were still pregnant at the time of abstract submission. DTG use was five times higher in 2017 compared to 2015 (Figure 1). All deliveries resulted in live fetuses with negative HIV status, although there was one fetus from a twin pregnancy with a congenital abnormality. The majority of women were diagnosed with HIV before pregnancy (84%), were already on DTG when entering pregnancy (63%) and remained on the same regimen until labor and delivery (Table 1).
We found that DTG use is increasing among a clinic cohort of pregnant women with HIV with signs of treatment tolerability during pregnancy. The risk of teratogenicity will need to be fully assessed as more clinics report fetal outcomes among infants exposed to DTG.
H. Nkwihoreze, None
E. Aaron, None
G. Alleyne, None
F. Momplaisir, None